A New Era Dawns: Grander’s Bold Leap Transforms into PolarityTE’s Private Vanguard
SALT LAKE CITY, Aug. 22, 2023 /PRNewswire/ — Amidst a symphony of anticipation, Grander Acquisition LLC (the “Company”), guided by the visionary Michael Brauser, proudly announces the closing of its acquisition. A transformation has occurred, as the Company now stands as the vanguard of innovation under the revered banner of RegenETP, Inc. (previously known as PolarityTE, Inc.). This biotechnology beacon once known as PolarityTE has been weaving dreams of regenerative tissue products, and today, those dreams find renewed wings.
Within the treasure trove of assets lie the first-born of PolarityTE’s regenerative miracles: SkinTE®. The journey to rejuvenating tissue and lives has received the seal of approval, echoed by the open investigational new drug application (IND) for SkinTE® with the eminent U.S. Food and Drug Administration (FDA).
Behold, for the saga continues as the Company pens a new chapter, embarking on the first of two pivotal odysseys for SkinTE®. These expeditions are a clarion call to the biologics universe, a summons to carve a legacy in the chronicles of chronic cutaneous ulcers. The coffers of innovation have been replenished, ready to fuel the journey.
“We stand on the cusp of greatness as we embrace the PolarityTE assets. SkinTE® is not just a product; it’s a revelation, a beacon that will illuminate the realm of chronic wounds. Our leaders are not just captains; they are architects of this future. With unwavering resolve, we shall pave the path for SkinTE® to soar,” declared the visionary Michael Brauser, now the Chairman of this resolute voyage.
As the curtain rises on this new act, Grander enlists the maestro, John Stetson, to wield the baton as Chief Executive Officer. Dr. Nikolai Sopko, once the heartbeat of PolarityTE’s scientific prowess, now adorns the mantel of Chief Scientific Officer and Chief Operating Officer. A familiar face, Dr. Edward W. Swanson, co-founder of PolarityTE, takes the helm as President and Chief Medical Officer, steering this vessel through uncharted waters.
In this epoch of evolution, the echoes of Grander dissolve into the resonance of PolarityTE. The Company strides forth, a private entity with a public mission: to reimagine possibility, to mend what’s broken, and to shine as the North Star guiding regenerative innovation.
About Grander Acquisition LLC
Based in the vibrant city of Salt Lake City, Utah, Grander Acquisition LLC stands as a pioneering force in the realm of biotechnology. Their mission? Crafting a future where regenerative tissue products transform lives. At the forefront of their innovative lineup is SkinTE®, a remarkable creation poised to redefine possibilities.
With an investigational new drug application (IND) laid open before the U.S. Food and Drug Administration (FDA), Grander Acquisition LLC embarks on a quest, propelling SkinTE® into the spotlight. The journey includes two pivotal studies, illuminating the path toward a biologics license application (BLA) for addressing chronic cutaneous ulcers. SkinTE® – a beacon of hope, available for those who dare to explore its investigational marvel.